[1]. Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X, He J. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017, 10;401:63-71.
[2]. Hao Yang, Feng Fang, Ruimin Chang, Lianyue Yang. MicroRNA-140-5p Suppresses Tumor Growth and Metastasis by Targeting Transforming Growth Factor b Receptor 1 and Fibroblast Growth Factor 9 in Hepatocellular Carcinoma. HEPATOLOGY. 2013, 58;205-217.
[3]. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997,20;385(6618): 729-33.
[4]. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009,15(20):2319-35.
[5]. Sun J, Jiang J, Lu K, Chen Q, Tao D, Chen Z. Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-α signalling pathways. Mol Cell Biochem. 2017,426(1-2):17-26.
[6]. Liu H B, Zhu Y, Yang QC, Shen Y, Zhang XJ, Chen H. Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma. Genet Mol Res. 2015, 14(2): 4391-8.
[7]. Zhang C, Han X, Xu X, Zhou Z, Chen X, Tang Y, Cheng J, Moazzam NF, Liu F, Xu J, Peng W, Du F, Zhang B, Song Z, Zeng J, Gong A. FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma. Cell Death Dis. 2018, 9(5): 469.
[8]. Hu B, Meng X, Zhang Y, Hossain MM, Wu L, Zhang Y, Peng X, Zhang X. Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF‑7 cells in vitro and in vivo and its mechanism of action. Oncol Rep. 2018,39(4): 1640-1648.
[9]. Wang H P, Wang X, Gong LF, Chen WJ, Hao Z, Feng SW, Wu YB, Ye T, Cai YK. Nox1 promotes colon cancer cell metastasis via activation of the ADAM17 pathway. Eur Rev Med Pharmacol Sci. 2016,20(21): 4474-4481.
[10]. Yang X W, Zhang LJ, Huang XH, Chen LZ, Su Q, Zeng WT, Li W, Wang Q. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res. 2014. 44(5): 551-559.
[11]. Liu Y, Wu C, Wang Y, Wen S, Wang J, Chen Z, He Q, Feng D. Micro RNA- 145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma. Oncol Rep. 2014, 32(5): 1923-30.
[12]. Marchenko G N, Marchenko ND, Strongin AY. The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem J. 2003,372: 503-15.
[13]. Ahokas K, Lohi J, Illman SA, Llano E, Elomaa O, Impola U, Karjalainen- Lindsberg ML, Saarialho-Kere U. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Laboratory investigation; a journal of technical methods and pathology. 2003,83(12): 1887-99.
[14]. Wu T, Li Y, Lu J, Qiao Q, Bao G, Wang N, He X, Du X. Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer. Med Oncol. 2013, 30(1): 323.
[15]. Pu Y, Wang L, Wu H, Feng Z, Wang Y, Guo C. High MMP-21 expression in metastatic lymph nodes predicts unfavorable overall survival for oral squamous cell carcinoma patients with lymphatic metastasis. Oncol Rep. 2014,31(6): 2644-50.
[16]. Zhang Shu-liang, Liu Ling. microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1. EXPERIMENTAL AND THERAPEUTIC MEDICINE. 2015, 9(2), 579-584.
[17]. Xu Jiangfeng, Li Xuedong, Yang Hao, Chang R, Kong C, Yang L. SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition. CANCER, 2013,119 (12); 2247-2257.
[18]. Fang Feng, Chang Ruimin, Yang Lianyue. Heat Shock Factor 1 Promotes Invasion and Metastasis of Hepatocellular Carcinoma In vitro and In Vivo. Cancer, 2012,118(7); 1782-1794.
[19]. Zhao Z, Yan L, Li S, Sun H, Zhou Y, Li X. Increased MMP-21 expression in esophageal squamous cell carcinoma is associated with progression and prognosis. Med Oncol. 2014,31(8): 91.
[20]. J Z, Pan Q, Yan W, Wang Y, He X, Zhao Z. Overexpression of MMP21 and MMP28 is associated with gastric cancer progression and poor prognosis. Oncology letters. 2018,15(5): 7776-7782.
[21]. Sung Woo Hong, Wonhee Hur, Jung Eun Choi, Jung-Hee Kim, Daehee Hwang, Seung Kew Yoon. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. Oncotarget. 2016,7(17): 23482-97.
[22]. Li Y, Ren Z, Wang Y, Jung-Hee Kim, Daehee Hwang, Seung Kew Yoon. ADAM17 promotes cell migration and invasion through the integrin β1 pathway in hepatocellular carcinoma. Experimental cell research. 2018,370(2): 373-382.
[23]. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997,385(6618): 733-6.
[24]. Caescu C I, Jeschke GR, Turk BE. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J. 2009,424 (1):79-88.
[25]. Tucher J, Linke D, Koudelka T, Cassidy L, Tredup C, Wichert R, Pietrzik C, Becker-Pauly C, Tholey A. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries. J Proteome Res. 2014,13(4): 2205-14.
[26]. Huang Y, Li W, Chu D, Zheng J, Ji G, Li M, Zhang H, Wang W, Du J, Li J. Overexpression of matrix metalloproteinase-21 is associated with poor overall survival of patients with colorectal cancer . J Gastrointest Surg. 2011,15(7): 1188-94.